<DOC>
	<DOCNO>NCT01877746</DOCNO>
	<brief_summary>The aim study compare effect combine immunosuppressive therapy give top standard medical therapy chronic heart failure accord current guideline standard medical therapy chronic heart failure alone patient infammatory cardiomyopathy ( ICM ) . Suitable subject characterize EMB establish presence myocardial inflammation / negative polymerase chain reaction assay ( PCR ) finding cardiotropic infectious agent vary duration heart failure symptom leave ventricular ( LV ) systolic dysfunction ( phase A ) . Further , compare effect two regimen combine immunosuppressive therapy patient ICM ( phase B ) .</brief_summary>
	<brief_title>CZECH-ICIT ( CZECH Inflammatory Cardiomyopathy Immunosuppression Trial )</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>1 . Males female age 18 65 year time signing inform consent 2 . Signing informed consent . 3 . LV systolic dysfunction define ejection fraction less than/or equal 40 % assessed echocardiography symptom heart failure ( minimum NYHA class II ) last least 2 week time randomization . This criterion also determine inclusion study subject one two substudies ( CZECHICIT 1 CZECHICIT 2 ) . LV systolic dysfunction ( define ejection fraction less than/or equal 40 % ) symptoms heart failure ( minimum NYHA class II ) last 2 week 6 month , standard medical therapy chronic heart failure give least 2 week subject fulfills criterion inclusion CZECHICIT 1 substudy LV systolic dysfunction ( define ejection fraction less than/or equal 40 % ) symptoms heart failure ( minimum NYHA class II ) last 6 month , standard medical therapy chronic heart failure give least 2 week subject fulfills criterion inclusion CZECHICIT 2 substudy 4 . Positive immunohistochemistry find myocardial inflammation endomyocardial biopsy ( EMB ) . EMB must perform 6 week prior inclusion study . Positive immunohistochemistry EMB find demonstrate myocardial inflammation define presence least 7/mm2 cluster differentiation 3 ( CD3 ) positive lymphocyte and/or least 14 infiltrate leucocyte ( LCA+ cell ) /mm2 specimen . 5 . The absence infectious agent EMB define negative result PCR test EMB specimen . PCR test aim exclude presence enterovirus ( ECHO , coxsackie ) , adenoviruses , herpes virus ( herpes simplex virus ( HSV1 ) , EpsteinBarr virus ( EBV ) , cytomegalovirus ( CMV ) , human herpes virus ( HHV6 ) ) , Borrelia burgdorferi parvovirus B19 . In case parvovirus B19 , negative PCR result consider less 500 viral copies/ug genomic DNA detect . EMB must perform 6 week prior inclusion study . 6 . Negative blood pregnancy test fertile female . 7 . Usage effective method contraception ( hormonal 2 barrier method contraception ) 1 . The presence coronary artery disease , define angiographic finding one coronary artery stenosis &gt; 50 % , history previous myocardial infarction and/or percutaneous surgical myocardial revascularization . Coronary angiography must perform 2 year randomization study . 2 . Permanent pacemaker include cardiac resynchronization therapy . 3 . The presence uncontrolled , persistent supraventricular tachyarrhythmia , ventricular rate &gt; 120/min , last 1 week EMB . 4 . The presence uncontrolled arterial hypertension , define blood pressure value &gt; 180mmHg ( systolic pressure ) and/or 110mmHg ( diastolic pressure ) last 3 month . 5 . The presence least moderately hemodynamically significant primary valvulopathy congenital heart disease ( apart patent foramen ovale nonsignificant atrial septal defect ) . 6 . Previous heart valve surgery ( replacement reconstruction ) surgical correction congenital heart disease . adu . 7 . A history cytostatic therapy radiotherapy . 8 . Alcoholism define ethanol intake &gt; 90 g/day . 9 . The presence uncontrolled endocrine metabolic disorder . 10 . Gravidity lactation . 11 . Known hypersensitivity investigational drug . 12 . All contraindication immunosuppressive therapy accord Summary product characteristic ( SmPC ) investigational medicinal product : untreated systemic infection , poorly manageable diabetes mellitus , osteoporosis , florid gastric duodenal ulcer , uncontrolled arterial hypertension , history malignant disease oncological treatment finish less 5 year , proven immunodeficiency , renal hepatic insufficiency ( serum creatinine &gt; 200 Âµmol/l ; alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) activity great three time standard ) , leukocytopenia ( leucocytes less 4 x 10 9/l ) , thrombocytopenia ( platelet le 100 x 10 9/l ) , anemia ( hemoglobin concentration le 100 g/l ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>ICM</keyword>
	<keyword>myocarditis</keyword>
	<keyword>cardiomyopathy</keyword>
	<keyword>endomyocardial biopsy</keyword>
	<keyword>immunosuppression</keyword>
</DOC>